nach oben

Die Chirurgie

Erschienen in:

31.03.2022 | Pankreaskarzinom | Leitthema

Chirurgische Therapie des Pankreaskarzinoms – was gibt es Neues?

verfasst von: Univ.-Prof. Dr. Dr. med. Thomas Schmidt, Orlin Belyaev, Waldemar Uhl, Christiane J. Bruns

Erschienen in: Die Chirurgie | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Inzidenz des duktalen Adenokarzinoms des Pankreas steigt weiterhin und es wird bis 2030 zur zweithäufigsten krebsbedingten Todesursache in Europa und den USA aufsteigen. Mit einer 5‑Jahres-Überlebensrate von nur bis zu 10 % hat es weiterhin eine sehr schlechte Prognose. Die chirurgische Tumorresektion stellt die einzige kurative Therapieoption dar, die inzwischen zum Teil durch multimodale neoadjuvante und adjuvante Therapiekonzepte unterstützt wird. Aufgrund der aggressiven Tumorbiologie können Patienten insbesondere bei fortgeschrittenen Pankreaskarzinomen von diesen multimodalen Therapiekonzepten profitieren. Daneben wurden in den letzten Jahren die chirurgische Therapie optimiert, die Resektabilität anhand verschiedener Kriterien klarer definiert und minimal-invasive Operationen in der Breite eingeführt. Die aktuelle Übersichtsarbeit fasst die neuesten Entwicklungen und die neue S3-Leitlinie zum Thema Chirurgie beim Pankreaskarzinom zusammen.

Ducreux M et al (2015) Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v56–v68PubMedCrossRef

Siegel RL et al (2021) Cancer statistics. CA Cancer J Clin 71(1):7–33PubMedCrossRef

Rahib L et al (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74(11):2913–2921PubMedCrossRef

Brunner M et al (2021) Indications for the surgical management of pancreatic neoplasms. Z Gastroenterol. https://doi.org/10.1055/a-1682-7456. Online ahead of printCrossRefPubMed

Takaori K et al (2016) International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. Pancreatology 16(1):14–27PubMedCrossRef

Hank T et al (2018) Validation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tail. Br J Surg 105(9):1171–1181PubMedCrossRef

Strobel O et al (2017) Pancreatic cancer surgery: the new R‑status counts. Ann Surg 265(3):565–573PubMedCrossRef

Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, D.K., AWMF), S3-Leitlinie zum exokrinen Pankreaskarzinom, Langversion 2.0, 2021, AWMF Registernummer: 032-010OL. 2021.

Isaji S et al (2018) International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology 18(1):2–11PubMedCrossRef

10.

Persigehl T et al (2020) Structured reporting of solid and cystic pancreatic lesions in CT and MRI: consensus-based structured report templates of the German Society of Radiology (DRG). Rofo 192(7):641–656PubMedCrossRef

11.

Wittel UA et al (2019) Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma—results of the Conko-007 multicenter trial. BMC Cancer 19(1):979PubMedPubMedCentralCrossRef

12.

Jang JK et al (2021) CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy. Eur Radiol 31(2):813–823PubMedCrossRef

13.

Marchegiani G et al (2018) Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection. Eur Radiol 28(10):4265–4273PubMedCrossRef

14.

Jeon SK et al (2022) How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers. Eur Radiol 32(1):56–66PubMedCrossRef

15.

Hartwig W et al (2013) CA19‑9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol 20(7):2188–2196PubMedCrossRef

16.

Negoi I et al (2018) Surgical anatomy of the superior mesenteric vessels related to pancreaticoduodenectomy: a systematic review and meta-analysis. J Gastrointest Surg 22(5):802–817PubMedCrossRef

17.

Hackert T et al (2017) The TRIANGLE operation—radical surgery after neoadjuvant treatment for advanced pancreatic cancer: a single arm observational study. HPB 19(11):1001–1007PubMedCrossRef

18.

Schneider M et al (2019) Pancreatic resection for cancer-the Heidelberg technique. Langenbecks Arch Surg 404(8):1017–1022PubMedCrossRef

19.

Mitchem JB et al (2012) Long-term results of resection of adenocarcinoma of the body and tail of the pancreas using radical antegrade modular pancreatosplenectomy procedure. J Am Coll Surg 214(1):46–52PubMedCrossRef

20.

Zhou Q et al (2019) Assessement of postoperative long-term survival quality and complications associated with radical antegrade modular pancreatosplenectomy and distal pancreatectomy: a meta-analysis and systematic review. BMC Surg 19(1):12PubMedPubMedCentralCrossRef

21.

Schmidt T et al (2020) Cavernous transformation of the portal vein in pancreatic cancer surgery-venous bypass graft first. Langenbecks Arch Surg 405(7):1045–1050PubMedPubMedCentralCrossRef

22.

Mihaljevic AL et al (2021) Not all Whipple procedures are equal: proposal for a classification of pancreatoduodenectomies. Surgery 169(6):1456–1462PubMedCrossRef

23.

Nagakawa Y et al (2021) Surgical outcomes of pancreatectomy with resection of the portal vein and/or superior mesenteric vein and jejunal vein for pancreatic head cancer: a multicenter study. Ann Surg. https://doi.org/10.1097/SLA.0000000000005330. Online ahead of printCrossRefPubMed

24.

Malczak P et al (2020) Arterial resections in pancreatic cancer—Systematic review and meta-analysis. HPB 22(7):961–968PubMedCrossRef

25.

Ironside N et al (2018) Meta-analysis of an artery-first approach versus standard pancreatoduodenectomy on perioperative outcomes and survival. Br J Surg 105(6):628–636PubMedCrossRef

26.

Loos M et al (2022) Arterial resection in pancreatic cancer surgery: effective after a learning curve. Ann Surg 275(4):759–768. https://doi.org/10.1097/SLA.0000000000004054CrossRefPubMed

27.

Diener MK et al (2021) Periarterial divestment in pancreatic cancer surgery. Surgery 169(5):1019–1025PubMedCrossRef

28.

Cai B et al (2021) Sub-adventitial divestment technique for resecting artery-involved pancreatic cancer: a retrospective cohort study. Langenbecks Arch Surg 406(3):691–701PubMedCrossRef

29.

Damanakis AI et al (2019) Proposal for a definition of „Oligometastatic disease in pancreatic cancer“. BMC Cancer 19(1):1261PubMedPubMedCentralCrossRef

30.

Crippa S et al (2020) A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy. Updates Surg 72(1):39–45PubMedCrossRef

31.

Hackert T et al (2017) Radical surgery of oligometastatic pancreatic cancer. Eur J Surg Oncol 43(2):358–363PubMedCrossRef

32.

Pausch TM et al (2021) Survival benefit of resection surgery for pancreatic ductal adenocarcinoma with liver metastases: a propensity score-matched SEER database analysis. Cancers 14(1):57. https://doi.org/10.3390/cancers14010057CrossRefPubMedPubMedCentral

33.

Gebauer F et al (2021) Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5‑fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC). BMC Cancer 21(1):1239PubMedPubMedCentralCrossRef

34.

Crippa S et al (2020) Positive neck margin at frozen section analysis is a significant predictor of tumour recurrence and poor survival after pancreatodudenectomy for pancreatic cancer. Eur J Surg Oncol 46(8):1524–1531PubMedCrossRef

35.

Zhang B et al (2021) Revision of pancreatic neck margins based on intraoperative frozen section analysis is associated with improved survival in patients undergoing Pancreatectomy for ductal Adenocarcinoma. Ann Surg 274(2):e134–e142PubMedCrossRef

36.

Nitschke P et al (2017) Impact of Intraoperative re-resection to achieve R0 status on survival in patients with pancreatic cancer: a single-center experience with 483 patients. Ann Surg 265(6):1219–1225PubMedCrossRef

37.

Crippa S et al (2021) Improved survival after pancreatic re-resection of positive neck margin in pancreatic cancer patients. A systematic review and network meta-analysis. Eur J Surg Oncol 47(6):1258–1266PubMedCrossRef

38.

Versteijne E et al (2018) Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg 105(8):946–958PubMedPubMedCentralCrossRef

39.

Versteijne E et al (2020) Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol 38(16):1763–1773PubMedPubMedCentralCrossRef

40.

Jang JY et al (2018) Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg 268(2):215–222PubMedCrossRef

41.

Birrer DL et al (2021) Neoadjuvant therapy for Resectable pancreatic cancer: a new standard of care. Pooled data from 3 randomized controlled trials. Ann Surg 274(5):713–720PubMedCrossRef

42.

van Dam JL et al (2022) Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomised controlled trials. Eur J Cancer 160:140–149PubMedCrossRef

43.

Ferrone CR et al (2015) Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 261(1):12–17PubMedCrossRef

44.

Kunzmann V et al (2021) Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 6(2):128–138PubMedCrossRef

45.

Suker M et al (2016) FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol 17(6):801–810PubMedPubMedCentralCrossRef

46.

Tsai S et al (2020) Importance of normalization of CA19‑9 levels following neoadjuvant therapy in patients with localized pancreatic cancer. Ann Surg 271(4):740–747PubMedCrossRef

47.

Heger U et al (2020) Induction chemotherapy in pancreatic cancer: CA 19‑9 may predict resectability and survival. HPB 22(2):224–232PubMedCrossRef

48.

de Rooij T et al (2019) Minimally invasive versus open distal pancreatectomy (LEOPARD): a multicenter patient-blinded randomized controlled trial. Ann Surg 269(1):2–9PubMedCrossRef

49.

Korrel M et al (2021) Minimally invasive versus open distal pancreatectomy: an individual patient data meta-analysis of two randomized controlled trials. HPB 23(3):323–330PubMedCrossRef

50.

Korrel M et al (2021) Long-term quality of life after minimally invasive vs open distal pancreatectomy in the LEOPARD randomized trial. J Am Coll Surg 233(6):730–739PubMedCrossRef

51.

van Hilst J et al (2019) Oncologic outcomes of minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Eur J Surg Oncol 45(5):719–727PubMedCrossRef

52.

van Hilst J et al (2019) Minimally invasive versus open distal pancreatectomy for ductal adenocarcinoma (DIPLOMA): a pan-European propensity score matched study. Ann Surg 269(1):10–17PubMedCrossRef

53.

van Hilst J et al (2019) Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial. Lancet Gastroenterol Hepatol 4(3):199–207PubMedCrossRef

54.

Wang M et al (2021) Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours: a multicentre, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol 6(6):438–447PubMedCrossRef

55.

Nickel F et al (2020) Laparoscopic versus open pancreaticoduodenectomy: a systematic review and meta-analysis of randomized controlled trials. Ann Surg 271(1):54–66PubMedCrossRef

56.

Liu Q et al (2021) Perioperative and oncological outcomes of robotic versus open pancreaticoduodenectomy in low-risk surgical candidates: a multicenter propensity score-matched study. Ann Surg. https://doi.org/10.1097/SLA.0000000000005160. Online ahead of printCrossRefPubMed

57.

Krautz C et al (2018) Effect of hospital volume on in-hospital morbidity and mortality following pancreatic surgery in Germany. Ann Surg 267(3):411–417PubMedCrossRef

58.

Finks JF, Osborne NH, Birkmeyer JD (2011) Trends in hospital volume and operative mortality for high-risk surgery. N Engl J Med 364(22):2128–2137PubMedPubMedCentralCrossRef

59.

de Wilde RF et al (2012) Impact of nationwide centralization of pancreaticoduodenectomy on hospital mortality. Br J Surg 99(3):404–410PubMedCrossRef

60.

Uhl W et al (2021) Statement of the surgical working group for liver, gall bladder and pancreatic diseases (CALGP) of the German Society for General and Visceral Surgery (DGAV) on rapid report V19-03: association between volume of cases and quality in complex pancreatic surgery. Chirurg 92(5):444–447PubMedCrossRef

Titel: Chirurgische Therapie des Pankreaskarzinoms – was gibt es Neues?
verfasst von: Univ.-Prof. Dr. Dr. med. Thomas Schmidt
Orlin Belyaev
Waldemar Uhl
Christiane J. Bruns
Publikationsdatum: 31.03.2022
Verlag: Springer Medizin
Schlagwörter: Pankreaskarzinom
Pankreaskarzinom
Pankreaskopfresektion
Pankreaskopfresektion
Erschienen in: Die Chirurgie / Ausgabe 5/2022
Print ISSN: 2731-6971
Elektronische ISSN: 2731-698X
DOI: https://doi.org/10.1007/s00104-022-01618-7

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Chirurgische Therapie des Pankreaskarzinoms – was gibt es Neues?

Zusammenfassung

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2022

Diagnostik beim Pankreaskarzinom – Update in der neuen S3-Leitlinie

Kombinierte Resektion und Ablation bei multiplen hepatozellulären Karzinomen – eine Validierungsstudie

Molekularpathologie in der Behandlung des Lungenkarzinoms – interdisziplinärer Blick auf die thoraxchirurgische Bedeutung

Laparoskopische Sentinel-Lymphknoten-Chirurgie – ein Verfahren zur Reduktion der operativen Radikalität beim Magenkarzinom

S3-Leitlinie „Adulte Weichgewebesarkome“

Besteht hier eine Indikation zur Thyreoidektomie?

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie